Portfolia Launches Women’s Health Fund IV; Announces Gameto Investment

Portfolia Founder & CEO Trish Costello. Image: Portfolia

Portfolia has launched Women’s Health Fund IV, making its debut investment in biotechnology company Gameto as part of the startup’s $44 million Series C round. The investment builds on Portfolia’s position as an early venture capital fund focused on women’s health investing.

Gameto develops stem cell therapies for reproductive health, with its lead program Fertilo using engineered ovarian support cells to mature eggs outside the body. The technology reduces standard IVF hormone protocols from two weeks to 2-3 days and has begun enrolling patients in a Phase 3 trial in the United States.

Women’s Health Fund IV expands Portfolia’s portfolio to 46 health investments across fertility, menopause, autoimmune disease, oncology, cardiovascular health, and mental health. Previous investments include Maven Clinic, which became the first U.S. unicorn in women’s health, along with HeraBiotech, Mirvie, and EverlyHealth.

The fund targets three categories: Women-specific conditions such as fertility and menopause; conditions that affect women differently, including cardiovascular disease and diabetes; and conditions that disproportionately affect women, such as autoimmune disease and osteoporosis.

“At Portfolia, we activate women to invest in the health solutions that will enhance our lives,” said Trish Costello, Founder & CEO of Portfolia. “Women’s health is compromised daily when investment dollars are not available to fuel new women’s health innovations.”

The women’s health market is estimated at over $600 billion globally, with sub-sectors including menopause ($20 billion), fertility ($50+ billion), and female-focused longevity therapeutics ($20 billion). Despite this market size, women’s health receives just 2% of health-related venture capital funding.

Portfolia operates with nearly 2,000 investing members across 20 countries and 50 states, with 15 funds making over 165 investments from pre-seed to pre-IPO companies. Women’s Health Fund IV is open to accredited investors, qualified purchasers, and family offices.

The fund addresses the gap between women making 80% of healthcare decisions while facing persistent gaps in diagnosis, treatment, and quality of care in the current healthcare system.